VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16
TEL AVIV, Israel, Aug. 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 16 at 8:30am Eastern Time to report second quarter ended June 30, 2018 financial results.
Thursday, August 16th@ 8:30am Eastern Time US Domestic: 877-222-6394 International: 703-925-2702 Conference ID: 3572709 Webcast: https://edge.media-server.com/m6/p/9dz8zzo9 Replays, Available through August 30, 2018 US Domestic: 855-859-2056 International: 404-537-3406 Conference ID: 3572709
About VBL Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:Michael RiceLifeSci Advisorsmrice@lifesciadvisors.com(646) 597-6979